Royal Philips has completed the acquisition of Northern Ireland-based medical device company PathXL in a bid to expand its digital pathology solutions offerings.
Pathology includes evaluation of patient tissue samples, which is instrumental in the diagnosis and treatment of a broad range of diseases, including cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Founded in 2004, PathXL offers services in the field of digital pathology, which includes image analysis, workflow software and educational tools.
Philips Digital Pathology Solutions general manager Russ Granzow said: "With this acquisition, we are accelerating our drive to support global medical institutions in their transition to digitised pathology workflows.
"Together with PathXL we see a unique opportunity to amplify our combined technology leadership positions.
"We will be able to offer an intelligent and integrated solution that fulfills many needs in computational pathology, education, workflow solutions and image analytics. These important and growing disciplines within pathology will enable a high-quality quantitative analysis of digital whole slide images."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDigital pathology allows the pathologists to review and share large sets of clinical data leveraging on the image analytics to assist in improving the quality of diagnosis with the potential to enable new therapies and ultimately improve patient outcomes.
Philips’s lntelliSite Pathology Solution is an automated digital pathology image creation, management and viewing system, which features an ultra-fast pathology slide scanner, an image management system and dedicated software tools.
Image: Lab technician using Philips IntelliSite ultra-fast scanner. Photo: courtesy of Royal Philips.
